Until now, only one high-affinity small-molecule inhibitor, AZD8797, and an anti-CX3CR1 nanobody are in phase 1 clinical trials to treat cancer pain and kidney disease, respectively [64,65]. Here, CX3CR1 is linked to kidney disorder.